Immutep (ASX:IMM) announced the initiation of the AIPAC-003 Phase 2/3 clinical trial of its eftilagimod alpha in combination with paclitaxel for treating metastatic HER2-neg/low breast cancer. …
Immutep announces initiation of Phase 2/3 trial of 'efti' in metastatic breast cancer
April 17, 2023 Australian Biotech
Latest Video
New Stories
-
Novartis names Anne Harris to lead Australia and New Zealand
July 20, 2026 - - Latest News -
Why is the system slower than when there was no patient involvement or input?
July 20, 2026 - - Latest News -
No company in its right mind would risk a large private market for this outcome?
July 20, 2026 - - Latest News -
The 'Dispatched' Podcast - Series 5, Ep .24
July 17, 2026 - - Podcast -
Ex-Novartis leader joins the board of emerging nuclear medicine company
July 17, 2026 - - Latest News -
It doesn't always feel like it, but make no mistake, this is what winning looks like
July 17, 2026 - - Latest News -
Telix opens Australia's first integrated radiopharmaceutical facility in Melbourne
July 16, 2026 - - Latest News